clinical trial · NCT05923073
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
Janssen Research & Development, LLC·phase3·recruiting·n = 120
Crohn's DiseaseGuselkumabGuselkumab
brief summary
The purpose of this study is to evaluate the clinical and endoscopic efficacy of guselkumab in pediatric participants with Crohn's Disease (CD) at the end of maintenance therapy (Week 52) among participants who were in clinical response to guselkumab at Week 12.
started
Mar 13, 2024
primary completion
Oct 27, 2027
completion
Jul 12, 2028
last updated
Jul 6, 2026
official title
A Phase 3, Multicenter, Randomized, Platform Study of p19 Inhibition of the IL-23 Pathway to Establish Efficacy in Pediatric Crohn's Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol